COPENHAGEN, Denmark, February 7 /PRNewswire-FirstCall/ -- Fertin Pharma announces that the company will launch a new nicotine gum on the US store brand market in collaboration with Perrigo.
Fertin Pharma started shipping nicotine gum to the US in December 2004. The company has entered into collaboration with Perrigo, America's largest supplier of over-the-counter (non-prescription) pharmaceutical and nutritional products for the store brand and contract manufacturing markets.
The new 2 mg and 4 mg nicotine gum will be produced in regular, orange and mint flavors and will be Fertin Pharma's first launch in the USA. Perrigo received approval from the U.S. Food and Drug Administration (FDA) to market the products in October 2004, indicated as an aid to smoking cessation.
Ralf Auerbach, General Director at Fertin Pharma said: "We have very big expectations around our collaboration with Perrigo. The new nicotine gum products are produced at our new facilities and are of the highest quality. In collaboration with Perrigo - America's largest store brand distributor - we believe that we can achieve a leading position in the store brand market for nicotine gum".
John Hendrickson, Perrigo Executive Vice President and General Manager, Consumer Healthcare said, "We are very excited to initiate our market launch of nicotine gum for the US store brand market. It is a strategically important product and category for us. We are very pleased to have developed a strong business relationship with Fertin Pharma and look forward to a bright future as we build a leading market position in the store brand smoking cessation category".
Medical Chewing Gum
Fertin Pharma's main business is the development and production of nicotine gum, but the company sees big opportunities within other medical product areas.
"Medical chewing gum has a number of decisive benefits compared with traditional delivery" says Ms Annette Agerskov, Deputy General Director at Fertin Pharma. "Chewing gum is easy to administer, it provides a fast onset of action, and is convenient for the user. We are currently investigating areas such as allergy, cough and cold, dyspepsia, migraine, obesity, osteoporosis, and pain".
ABOUT FERTIN PHARMA A/S
Company profile: http://www.fertin.com/index.php?id=39
This press release was published on behalf of Barfod Communications.
Nicotine gum in the USA
Fertin Pharma A/S